Bayer increases sales and earnings & #8211; leader in agriculture after acquisition

Group sales advance 4.5 percent (Fx& portfolio adj.) to 39.586 billion euros / EBITDA before special items increases by 2.8 percent to 9.547 billion euros, held back by currency effects of 457 million euros / Pharmaceuticals posts higher sales (Fx& portfolio adj.) and slightly lower earnings / Consumer Health: sales level with prior year (Fx& portfolio adj.), earnings decline / Crop Science reports sales gains, substantially higher earnings due to the acquisition, integration off to a strong start / Positive safety profile of glyphosate unchanged– Bayer vigorously defending itself against lawsuits/ Net income at 1.695 billion euros, impacted by one-time effects / Core earnings per share at 5.94 euros, above expectations / Net financial debt at 35.679 billion euros, significantly better than expected / Bayer confirms 2019 Group outlook and 2022 targets
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news